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Abstract
To study the effect of chronic excess growth hormone on adipose tissue, we performed
RNA sequencing in adipose tissue biopsies from patients with acromegaly (n = 7) or non-
functioning pituitary adenomas (n = 11). The patients underwent clinical and metabolic pro-
filing including assessment of HOMA-IR. Explants of adipose tissue were assayed ex vivo
for lipolysis and ceramide levels. Patients with acromegaly had higher glucose, higher insu-
lin levels and higher HOMA-IR score. We observed several previously reported transcrip-
tional changes (IGF1, IGFBP3, CISH, SOCS2) that are known to be induced by GH/IGF-1 in
liver but are also induced in adipose tissue. We also identified several novel transcriptional
changes, some of which may be important for GH/IGF responses (PTPN3 and PTPN4) and
the effects of acromegaly on growth and proliferation. Several differentially expressed tran-
scripts may be important in GH/IGF-1-induced metabolic changes. Specifically, induction of
LPL, ABHD5, and NRIP1 can contribute to enhanced lipolysis and may explain the elevated
adipose tissue lipolysis in acromegalic patients. Higher expression of TCF7L2 and the fatty
acid desaturases FADS1, FADS2 and SCD could contribute to insulin resistance. Cer-
amides were not different between the two groups. In summary, we have identified the acro-
megaly gene expression signature in human adipose tissue. The significance of altered
expression of specific transcripts will enhance our understanding of the metabolic and prolif-
erative changes associated with acromegaly.
Introduction
Acromegaly, i.e. excessive growth hormone (GH) production secondary to a pituitary ade-
noma, is a rare condition with an annual incidence of 3 patients per million [1]. The excess GH
has important metabolic effects; the two most significant effects of GH on metabolism in
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adipose tissue are insulin resistance and lipolysis [2]. Insulin resistance, presenting as diabetes
or impaired glucose tolerance, is found in most acromegalic patients [3], and contributes to the
enhanced morbidity [4]. Growth hormone induces the expression and secretion of IGF-1, so
phenotypes associated with acromegaly may be due to either GH signaling, IGF-1 signaling or
a combination of both [5,6].
There are few studies addressing the effect of GH specifically on the subcutanous adipose
tissue. Induction of STAT5 tyrosine phosphorylation and IGF1 mRNA expression has been
detected in human subcutaneous adipose tissue biopsies taken after acute GH administration
[7]. Subcutaneous adipocytes extracted from acromegalic patients are insulin resistant ex vivo,
and after a glucose tolerance test there was 50% less insulin binding to its receptor and
markedly decreased insulin-related anti-lipolytic activity [8]. In vivomeasurement in humans
detected GH-induced lipolysis in subcutanous adipose tissue [9]. Pharmacologic inhibition of
lipolysis reduced GH-induced insulin resistance, suggesting that some of this resistance is
dependent on higher abundance of free fatty acids [10]. Microarray of gene expression has
been published for subcutaneous adipose tissue biopsies before and after one year of GH treat-
ment in GH deficient patients [11].
To study the effects of chronic excess GH, we used unbiased RNA sequencing in adipose tis-
sue from acromegaly patients and controls. We found a distinctive pattern of changes in many
transcripts that are highly associated with acromegaly. Many of these alterations may contrib-
ute to the metabolic effect of GH and reveal novel mechanisms of GH-induced insulin resis-
tance and lipolysis in adipose tissue.
Materials and Methods
Patient Recruitment
The study was approved by the institutional review board of the University of Michigan Medi-
cal System. Written informed consent was obtained from all patients. Patients were recruited
consecutively from a cohort undergoing transsphenoidal adenomectomy at the University of
Michigan Medical Center for acromegaly or non-functioning pituitary adenoma over a 12
month period. All but one patient were newly diagnosed, none had previous surgery and only
one previously diagnosed patient was treated with a somatostatin analog but IGF1 was still
high without remission. None of the patients were on insulin, but one patient from each group
was treated with metformin. Two patients with non-secreting adenomas were treated with
beta blockers. Exclusion criteria were age<18 years old, current hormone treatment including
glucocorticoids, malignancy, inflammatory disease, diabetes type 1 and established pituitary
hormone deficiencies. For each patient, a data sheet was completed including, age, sex, anthro-
pometric measurements, diagnosis of hypertension, diabetes, results of blood tests and medica-
tions. Fasting blood samples were assayed for glucose (Siemens Advia 1800) and insulin (Life
Technologies) as instructed by the manufacturers.
Subcutaneous Fat Biopsy
During the course of pituitary surgery a routine subcutaneous fat graft is utilized to seal the
surgical field upon completion of the procedure. A total of 500 mg of this fat graft was used for
the study. ~200 mg were utilized for ex vivo lipolysis assay, ~300 mg was snap frozen in liquid
nitrogen and stored at -80 degrees for RNA preparation and ceramide analysis.
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Ex vivo Lipolysis
Twenty five mg pieces of adipose tissue were pre-incubated for 15 minutes in KRBH buffer
(sigma) at 37°C and then incubated for 1 hour at 37°C in 300 μl KRBH in the presence or
absence of isoproterenol 30nM in duplicate. Glycerol was assayed in supernatants using a glyc-
erol assay kit (sigma) as instructed by manufacturer.
Ceramide Determinations
Ceramide analysis of tissue samples was performed by liquid chromatography-triple quadru-
pole mass spectrometry (LC-QQQ) according to a modified version of the protocol reported in
[12]. Briefly, frozen tissue samples were pulverized under liquid nitrogen, then 20 mg portions
were extracted using 1.6 mL of a 2:1:0.8 mixture of chloroform:methanol:water containing
internal standards (50 ng each of C17 and C25 ceramide and C12 glucosylceramide per sam-
ple) [13]. The organic layer of the extract was dried under nitrogen gas and reconstituted in
100 uL of 60:40 acetonitrile: isopropanol. The re-constituted extract was analyzed by electro-
spray ionization LC-MS/MS on an Agilent (Santa Clara, CA) 6410 triple quadrupole instru-
ment operating in positive ion multiple reaction monitoring mode. The LC column used was a
Waters (Milford, MA) Xbridge C18 2.5 μ, 50 mm x 2.1 mm i.d. Mobile phase A was 5mM
ammonium acetate, adjusted to pH 9.9 with ammonium hydroxide; mobile phase B was 60:40
acetonitrile:isopropanol. The gradient consisted of a linear ramp from 50 to 100%B over 5 min-
utes, a 20 minute hold at 100%B, and re-equilibration at 50%B for 10 minutes. Injection vol-
ume was 25 μL. Ceramides and glucosylceramides were identified by retention time and by
MS/MS fragmentation parameters, and were quantitated by peak area relative to the closest-
matching internal standard using Agilent MassHunter Quantitative Analysis software.
Transcriptomic Analysis
Total RNA was extracted from adipose tissue using the RNEasy kit (Qiagen) and its quality
was verified using the Agilent 2100 Bioanalyzer (Agilent Technologies). At the University of
Michigan DNA Sequencing Core, cDNA libraries from polyA mRNA were prepared using
TruSeq cDNA synthesis kit and sequenced using a HiSeq 2000 (Illumina). Samples were run
on 2 lanes of a HiSeq 2000 (Illumina) generating 8 612 682 to 16 469 501 single-ended 50 bp
reads per sample. These were aligned to the human genome (Enembl GRCh37.74, Genbank
Assembly ID GCA_000001405.14) using TopHat version 2.0.10 [14], Bowtie 2 version 2.1.0
[15] and Samtools version 0.1.18. Reads were mapped to known genes using HTseq [16]. Gene
expression was analyzed using DESeq2 version 1.2.10 [17]. To account for potential age-depen-
dent changes in the subjects, we separated the patients into two groups, based on the median
value, under 60 years of age versus 60 and above as has been previously reported for acromeg-
aly studies [18]. We provide here both the non-age adjusted (S1 Table) and age-adjusted gene
expression changes (S2 Table).
We then added this age group as a covariate along with the disease state. We tested for inter-
actions between the age group and the disease state for each gene and did not identify any
interaction term after adjusting for multiple observations (q<0.05). All fold changes provided
in this manuscript are age-adjusted fold change values calculated from this regression.
We used Gene Set Enrichment Analysis (GSEA v2.0.13 [19,20]) to determine whether our
rank-ordered gene list for the comparison of acromegaly vs control patients is enriched in
genes from gene ontology, KEGG, transcription factor or microRNA target gene sets. The gene
list was ranked based on the shrunken log based 2 fold change and the statistical significance of
the enrichment score was determined by performing 1000 phenotype permutations and setting
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the enrichment statistics to classic. Other settings for GSEA pre-ranked were left by the soft-
ware default.
These subjects for whom RNAseq was performed corresponded to the patients described in
Table 1, with the exception of subjects 29 and 31 (both acromegaly patients), which had clinical
data but no RNAseq data. These data are available through the Gene Expression Omnibus
(GSE57803).
Statistics
All statistical tests were performed using the R (version 3.0.2,[21]). To correct for multiple
hypotheses, p-values were adjusted by the method of Benjamini and Hochberg [22] and
referred to in this manuscript as q-values. The age adjusted, p-value corrected for multiple is
denoted as q. Statistical significance was set at p/q<0.05 for most comparisons except for
GSEA analysis in which a p<0.25 was used.
Descriptive statistics such as means and standard deviations were determined for clinical
measurements. Student’s t-test was used to test the difference in means of these measurements
between control and acromegaly patients. Normality assumption was checked by Shapiro-Wilk
test. Wilcoxon rank sum test was performed for HOMA-IR score, insulin levels and the 14:0,
16:0, 20:0 ceramides and the C16:0 glucosylceramide species as these data were not normally
distributed. Welch’s t-test was used for basal lipolysis since the equal variance assumption was
rejected by Levene's test (car package version 2.0–19 [23]). Correlation coefficients were calcu-
lated by Pearson's product-moment.
Results and Discussion
Patient Characteristics
Clinical and metabolic measurements were obtained for 9 acromegaly patients and 11 controls.
Patient characteristics are shown in Table 1. There was no statistically significant difference in
body mass index (BMI), abdominal circumference or weight. Acromegaly patients were youn-
ger (p = 0.011) and taller than their controls (p = 0.036).
Acromegaly Patients Were More Insulin Resistant and Had Higher
Lipolysis
Acromegaly patients had elevated fasting glucose levels (p = 0.013) and higher fasted insulin
(p = 0.012, Fig 1A and 1B). When combined, we observed higher HOMA-IR scores in the acro-
megalic patients than in the controls (p = 0.001, Fig 1C), reflecting a significant decrease in
insulin sensitivity in the acromegaly patients, consistent with previous clinical findings [3].
Table 1. Clinical characteristics.
Control (n = 11) Acromegaly (n = 9) p
Age (years) 63.4 +/- 2.7 48.3 +/- 4.9 0.011
Height (cm) 170.0 +/- 2.4 180.1 +/- 4.0 0.036
Weight (kg) 89.4 +/- 6.7 103.9 +/- 9.3 0.21
BMI (kg/m2) 30.7 +/- 1.8 31.7 +/- 2.1 0.69
Abdominal Circumference (cm) 100.7 +/- 4.6 104.9 +/- 6.3 0.59
Data represents mean +/- standard error.
doi:10.1371/journal.pone.0129359.t001
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Subcutaneous adipose tissue chunks for lipolysis assay were available from 6 acromegaly
patients and 9 controls. The results suggested that acromegaly patients may have higher basal
lipolysis (p = 0.11), and higher lipolysis in the presence of isoproterenol (p = 0.058) even
though they did not achieve statistical significance (Fig 1D). These data are consistent with pre-
vious reports linking GH signaling with increased lipolysis [24].
Transcriptomic Analysis
To determine which genes are altered in adipose tissue in acromegaly subjects, we performed a
transcriptomic analysis of subcutaneous adipose tissue mRNA from 7 acromegalic patients and
11 controls. Patients separated along the first principal component approximately based on
their age, with 10/11 controls in one group and 7/8 of the acromegalic patients on the other
group (S1 Fig). This suggests that the major molecular differences between these groups can be
explained by the presence or absence of acromegaly.
After correcting for age, we identified 418 genes that had significantly different expression
in acromegaly. Of these, 198 genes were down-regulated and 290 were up-regulated in adipose
tissue from the acromegalic patients. These transcripts form a signature identifying transcrip-
tional differences in adipose tissue in response to long-term exposure to GH or indirectly to
IGF-1 (Fig 2A and S1 and S2 Tables).
In general, gene expression changes in acromegalic patients over 60 were smaller than in
patients under 60 (Fig 2B). Among genes that had significantly different expression, the fold
change for a gene was 25 +/- 2.3% higher in the younger cohort than the older cohort. This
effect was statistically significant via a Wilcoxon-Rank Sum test (p = 1.4 x 10−11).
Gene set enrichment analysis testing KEGG pathways [25,26] showed enrichment of genes
in the categories involved in metabolism, including upregulation of genes involved in the TCA
cycle, fatty acid metabolism, biosynthesis of unsaturated fatty acids as well as genes which
Fig 1. Acromegalic patients have reduced insulin sensitivity and trend for higher lipolytic activity than
their controls. A) Fasting blood glucose levels. B) Fasting insulin levels. C) HOMA-IR score from Control or
Acromegaly subjects. D) ex vivo lipolysis as measured by glycerol release from excised white adipose tissue
from control or acromegaly patients left untreated (Basal) or after stimulation with 30 nM isoproterenol (Iso).
Data is presented as mean +/- standard error of the mean. Asterisk indicates q<0.05.
doi:10.1371/journal.pone.0129359.g001
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Fig 2. Differential expression of genes in white adipose tissue from subjects with acromegaly
compared to controls. A) Heatmap of the differentially expressed genes in white adipose tissue. Individual
values are colored as the log fold change for a particular gene in a particular subject compared to the average
expression of that gene across all cohorts, with brown indicating less expression and green indicating more
expression (designated in the key as Row Z-score). The bar across the top indicates the subject’s diagnosis,
red for acromegaly and blue for controls. B) Scatterplot showing the log2 fold change for genes which had a
statistically significant difference (q<0.05) between acromegaly and control subjects. Each dot represents the
log2 fold change for acromegaly for a gene in the under 60 and 60 or over cohorts. The solid line represents a
slope of 1, which would imply no difference in fold change between age groups. The red line is a best fit line
with a lower slope, showing that on average the fold change for older patients is smaller than the fold change
for the under-60 patients.
doi:10.1371/journal.pone.0129359.g002
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regulate the cell cycle. We also observed downregulation of genes involved in pathways of
GPCR signaling, MAPK signaling, inflammation and protein synthesis (S3 Table). We also
examined the transcription factor networks that may underlie these changes in mRNA levels.
We identified an up-regulation of several candidate transcription factors and microRNA’s (S4
Table) whose targets are significantly altered in acromegalic subcutanous white adipose tissue
after adjusting for age. Notably among these are an up-regulation of E2F, GATA-1, MEF-2 and
CREB targets and a down-regulation of AP1, STAT1, 3, 4 and 6, PPARα, NF-κB and SRF
responsive genes.
Established GH Responsive Genes Are Up-Regulated in Adipose
Tissue from Acromegaly Patients
Since acromegaly is caused by an overproduction of GH, we first analyzed known GH respon-
sive genes. We found that expression of previously reported GH responsive genes, including
IGF1 (3.5 fold q = 1.65 x 10−6), and IGFBP3 (2.3 fold, q = 0.0002) are elevated in acromegalic
patients (Fig 3A and 3B). IGF-1 has been shown to be induced in adipocytes exposed to GH
[27], while there were no previous reports regarding IGFBP3 induction in adipose tissue. The
confirmation of these previously reported acromegaly or GH-induced transcriptional changes
strengthens our interpretation of other transcriptional changes. Neither the growth hormone
receptor (GHR) nor the IGF-1 receptors (IGF1R, IGF2R) was significantly altered in acrome-
galic adipose tissue.
There was a correlation between IGF1mRNA and levels of IGF-1 in serum in the acromegaly
patients (R2 = 0.51, p = 0.043; Fig 3C), reflecting that increased induction of IGF1 in adipose tis-
sue is similar in its extent to serum IGF1 induction. Serum IGF1 is primarily thought to be
derived from liver tissue due to the observation that serum IGF-1 levels are reduced 75% in a
liver specific IGF-1 knockout [28]. Our data demonstrates that expression of the adipose tissue
IGF1 gene correlates well with that of serum IGF-1. Note that the older subjects had lower serum
Fig 3. GH targets are differentially expressed in acromegaly subjects. A) mRNA Expression of A) IGF1 and B) IGFBP3 transcript levels in adipose tissue
from control and acromegalic patients (C) Comparason between IGF1mRNA and IGF-1 serum levels in patients with acromegaly (D and E) Expression of
mRNA for suppressors of growth hormone signaling (F) and Expression of tyrosine phosphatases associated with growth hormone signaling. Asterisks
indicate q<0.05 for the separated under 60 and 60 or over cohorts for panels A, B, D and E and for the age adjusted combined analysis for panel F. Barplots
are presented as mean +/- standard error of the mean.
doi:10.1371/journal.pone.0129359.g003
Analysis of Acromegalic Adipose Tissue
PLOS ONE | DOI:10.1371/journal.pone.0129359 June 18, 2015 7 / 16
IGF-1 than the younger subjects, indicating that circulating IGF-1 levels may correlate with gen-
erally reduced transcriptional changes observed in the older acromegalic patients (Fig 3C).
A Novel Negative Feedback Loop Is Induced by Chronic Exposure to
High GH/IGF-1 Levels
SOCS2 AND CISH, both suppressors of cytokine signaling that have been shown to be
important in down-regulating GH signaling, are up-regulated in acromegaly (1.7 and 2.3 fold
respectively (q = 0.003 and q = 0.00014, Fig 3D and 3E). These data suggest that feedback
mechanisms may be more active in younger patients, potentially either due to improved flexi-
bility or reduced duration of the disease. These have been shown to be induced in liver and
muscle by GH [29], and SOCS2 has also been reported to be induced in adipocytes by GH
[27,30]. We observed no significant differences in any PIAS genes.
We observed induction of the tyrosine phosphatases, PTPN3 (also called PTP-H1, 2.5 fold
higher q = 0.0028), PTPN4 (1.6 fold q = 0.00014) and PTPN13 (1.3 fold, q = 0.038) in acromeg-
aly (Fig 3F). PTPN3 has been reported to bind GH receptor in vitro in the presence of GH [31],
and its overexpression reduces STAT5 signaling in response to GH [32]. Ptpn3 Knockout mice
have excessive GH activity, as demonstrated by excessive growth accompanied by a strong
induction of liver IGF1mRNA and serum IGF-1 [32]. This is the first report of enhanced abun-
dance of PTPN3 mRNA in response to GH/IGF-1 exposure. The increased expression of
PTPN3 that we have observed in acromegaly suggests that this may be an additional negative
feedback pathway induced by GH and reducing GH/IGF-1 signaling.
Genes Controlling DNA Replication, Proliferation and Apoptosis
We observed a difference in expression of several different genes regulating cellular prolifera-
tion in acromegalic subjects. The KEGG category containing DNA replication was enriched
in acromegalic white adipose tissue, (S3 Table). Expression of Cyclin C (CCNC; 1.2 fold
q = 0.022), and Cyclin E (CCNE1; 2.9 fold, q = 6.5 x 10−5) which are important for transition
from G1 to S, were increased in acromegalic patients, and the negative regulator, cyclin depen-
dent kinase inhibitor B (CDKN2B) was decreased (40% reduced fold q = 0.016, S2A Fig).
CDKN2B has also been identified as a diabetes susceptibility gene identified in GWA studies
[33,34].
Additional DNA replication genes that were induced were nucleosome assembly protein
1-like 1 (NAP1L1, 1.3 fold q = 0.025) and origin recognition complex, subunit 2 (ORC2, 1.7
fold q = 0.0044), which are important for DNA replication, and the anti-apoptotic regulators
BAG4 (BCL2-associated athanogene 4. 1.7 fold q<10−4) and CAPN6 (calpain 6, 3.7 fold
q = 0.0011) were also induced (S2 Fig). Together these implicate increased cell division, poten-
tially of immune, vascular or pre-adipocyte cells in adipose tissue depots.
Apoptosis signal-regulating kinase 1 (MAP3K5) expression is higher in acromegaly (2.8 fold
q<0.0004), and there is also higher expression of its downstream substrates p38 α (MAPK14
1.2 fold q = 0.012), p38δ (MAPK13, 2.7 fold q<10−4). The effect of GH or IGF-1 on these tran-
scripts has not been reported before, and they could account for the effects of enhanced cell
proliferation and apoptosis in response to GH/IGF-1 [35].
Transcriptional Changes Regulating Lipid Metabolism and Localization
that May Contribute to Enhanced Lipolysis
To determine the potential causes of the increased lipolysis observed in Fig 1D, we examined
the expression of human lipases in these adipose tissues. We observed no significant difference
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in expression of the three classical triglyceride lipolysis enzymes hormone sensitive lipase
(LIPE), adipose triglyceride lipase (PNPLA) or monoglycerol lipase (MGLL; Fig 4A). Lipopro-
tein lipase (LPL), the lipase important for lipolysis of triglycerides in apolipoproteins, was
significantly more highly expressed in acromegaly patients (2.0 fold, q = 0.004). A strong
induction of LPL expression in response to GH and absence of change in HSL were demon-
strated before in a preadipocyte cell line [36–38] and in adipose tissue biopsies from GH defi-
cient patients after treatment with GH [11]. Studies that addressed LPL enzymatic activity and
not expression have found either no change or even a reduction in LPL activity in response to
GH treatment of human adipocytes in vitro [39,40].
Although neither Hormone Sensitive Lipase (LIPE) nor ATGL (PNPLA2) were altered, two
direct regulators of HSL and ATGL activity in adipocytes, abhydrolase domain containing 5
(ABHD5, also called CGI58 [41]), and nuclear receptor interacting protein 1 (NRIP (also called
RIP140 [42]) were expressed at higher levels in adipose tissue from acromegaly patients (2.3
fold q = 0.0016 and 1.7 fold, q = 0.043 Fig 4B). CGI58 is an allosteric activator of lipolytic activ-
ity and RIP140 regulates CGI58’s activity, therefore these data suggest that their transcriptional
up-regulation could contribute to the induction of lipolysis by GH/IGF-1. NRIP1 has also been
proposed to be a transcription regulator of genes involved in lipid and glucose metabolism [42]
and its induction could contribute to additional metabolic effects of GH/IGF-1 including dis-
rupted glucose metabolism. We also examined CIDEA/B/C and G0S2, which have also been
proposed to be positive regulators of lipolysis [43]. While there were no changes in the former,
we did observe a non-significant elevation in GOS2 (1.53 fold, q = 0.246; S2C Fig).
We next examined the expression of G-protein coupled receptors that induce lipolysis. The
β3 adrenergic (ADRB3) was more highly expressed in acromegaly patients compared to the
Fig 4. Expression changes of selected genes, potentially responsible for lipolytic or insulin sensitivity alterations in acromegaly patients.mRNA
Expression profile of genes potentially involved in lipid catabolism (A), regulation of lipolysis (B), fatty acid synthesis (C), fatty acid desaturation (D), TCF7L2
(E), and glucocorticoid signaling (F). Asterisks indicate q<0.05. Data indicates mean +/- standard error of the mean.
doi:10.1371/journal.pone.0129359.g004
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controls (5.2 fold, q = 0.0064). The β1 receptor was also more highly expressed in acromegalic
adipose tissue though it did not reach statistical significance (1.5 fold, q = 0.20; Fig 4B) suggest-
ing a potential sensitization of these patients to adrenergic stimuli may underlie the enhanced
ex vivo lipolysis.
In contrast to the lipolytic phenotype of acromegalic patients, several fatty acid and triglyc-
eride synthesis genes were expressed at higher levels in acromegaly patients (Fig 4C). These
include ACSS2 (1.6 fold, q = 0.044) and ACSS3 (1.7 fold, q = 0.064), which catalyze the activa-
tion of acetate for use in lipid synthesis. We also observed elevations in Acetoacetyl Co-A
synthase (AACS; 1.9 fold, q = 0.0066), Acetyl Co-A carboxylase (ACACA, 1.7 fold q = 0.039),
and Acyl-CoA synthetase long-chain family member 3 ACSL3 (1.3 fold, q = 0.045), which con-
vert long-chain fatty acids into fatty acyl-CoA esters. In addition, we also observed an elevation
in fatty acid synthase FASN (1.7 fold, q = 0.01) in the acromegaly patients. The first two steps
in triglyceride synthesis from fatty acids are catalyzed by glycerol-3-phosphate acyltransferase
9 (AGPAT1,2,3 and 5) and 1-acyl-sn-glycerol-3-phosphate acyltransferase (AGPAT9). We
observed transcriptional up-regulation of both AGPAT2 (42% increased, q = 0.02) and
AGPAT9 (7.6 fold increased, q = 2.7 x 10−4) in acromegaly patients. Via pathway analysis, both
fatty acid metabolism and unsaturated fatty acid biosynthetic pathways were up-regulated in
the acromegaly patients (see S2 Table and below). This up-regulation may represent compen-
sation by the adipose tissue due to enhanced lipid breakdown and oxidation in this and other
tissues in acromegaly patients.
With respect to glycogen metabolism, expression of muscle glycogen phosphorylase
(PYGM) was 3.2 fold higher (q = 0.00078) in the acromegaly patients (S2D Fig). The signifi-
cance of glycogen in adipose tissue, or changes in glycogen content in acromegalic adipose tis-
sue have not been characterized, but these findings would predict that the rates of
glycogenolysis in acromegalic white adipose tissue would be elevated.
Transcripts Altered in Acromegaly that May Contribute to Insulin
Resistance
One of the most pronounced differences between the acromegaly patients and the controls
was a greater than 4 fold higher expression (q<1x10-5; Fig 4D) of the three fatty acid desa-
turases—stearoyl-CoA desaturase (SCD, delta-9-desaturase), fatty acid desturase 1 (FADS1,
delta-5-desaturase) and fatty acid desturase 2 (FADS2, delta-6-desaturase). SCD products and
FADS2mRNA have also recently been shown to be induced by GH in mice [44]. The change in
expression of these enzymes could be a possible link between acromegaly and insulin resistance
due to an elevation of unsaturated fatty acids, as activity of FADS1 and FADS2 are associated
with metabolic syndrome [45,46].
We observed no decrease in expression of canonical transcripts important for insulin signal-
ing and response to insulin in adipocytes, including insulin receptor (INSR), IRS1, IRS2, AKT1-
3, or GLUT4 (SLC2A4; see S3A Fig). This indicates that the observed insulin resistance is not
caused by mRNA decreases in these genes. In fact, the KEGG category containing insulin sig-
naling genes was generally up-regulated in these tissues (S3 Table). AKT1 was significantly
higher (1.3 fold, q = 0.006) and the remainder of these genes trended to be more highly
expressed in the adipose tissue from the acromegalic and insulin resistant patients, potentially
underlying a transcriptional up-regulation that compensates for an alternative insulin resis-
tance mechanism.
One previously identified candidate is the phosphoinositide-3-kinase, regulatory subunit 1
(PIK3R1, also called p85α), which was induced by GH in mouse adipose tissue and thought to
contribute to GH-induced insulin resistance [47]. In our study PIK3R1 expression was not
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significantly different in the acromegaly patients, though it was modestly increased (25%
increased, q = 0.23).
The ERK kinase pathway was down-regulated in the acromegaly patients including a 2–4
fold lower expression of the downstream transcription factors FOS, JUN, JUNB (q<0.04, S2
Table and S3B Fig). Jun and Fos form the transcription factor AP1, which drives transcription
of many targets involved in differentiation, proliferation and apoptosis [48]. Globally, we also
found that AP1 targets were down-regulated. (ie, NES = -3.30, q<1 x 10−4 for V$AP1_Q4_01,
S4 Table).
The cytokine modulators STAT6 and the pro-inflammatory protein kinase IKKβ (IKBKB)
are expressed at lower levels (~18% reduced, q = 0.0034 for STAT6 and q = 0.009 for IKBKB).
Furthermore, the pro-inflammatory cytokines IL1B, IL6 and CCL2 (MCP-1) and the pro-
inflammatory protein kinase IKBKE all trend towards lower expression, and genes from several
KEGG pathways involved in inflammation were expressed at lower levels in the acromegaly
cohort (S2 Table and S3 Table and S3C Fig). These data support the hypothesis that insulin
resistance in these patients is not due to enhanced inflammatory signaling.
To test biochemically whether ceramides may play a role in the acromegaly associated insu-
lin resistance, we took a lipidomics approach to analyze ceramide and glucosylceramide species
from the adipose tissue explants of these patients. Elevated ceramides have been proposed to
mediate insulin resistance by several models [49–52]. We observed a modest down-regulation
of the mRNA levels of glycosylsphingolipid metabolic genes in our data (normalized enrich-
ment score = -0.86 q = 0.71). We then measured ceramide species from 7 acromegaly patients
and 11 control patients directly and observed no statistically significant changes in any cer-
amide species (S4 Fig, q-values all>0.25). We did however, detect modest elevations of C16:0,
C18:0 and C24:0 ceramide species in subcutanouse adipose tissue from acromegalic patients.
We therefore do not have strong evidence to support the hypothesis that ceramide elevations
are causative of insulin resistance in acromegalic white adipose tissue.
TCF7L2, a transcription factor regulating many metabolism genes that is also a diabetes sus-
ceptibility gene [53] is up-regulated in the acromegaly patients (1.5 fold, q = 0.00045, Fig 4E).
Mice with liver specific knockout of Tcf7l2 are hypoglycemic, while transgenic mice overex-
pressing liver Tcf7l2 are hyperglycemic [54]. TCF7L2 in subcutaneous fat is higher and expres-
sion of splice isoforms is reduced in subcutaneous fat and in liver following bariatric surgery
[55]. Higher expression of TCF7L2 could also therefore be linked to insulin resistance in
acromegaly.
Glucocorticoid Regulation
11βHydroxysteroid dehydrogenase 1 (HSD11B1), the enzyme that activates transformation of
cortisone to cortisol, was reduced over 4 fold in acromegaly patients (q = 0.0048, Fig 4F). The
down-regulation of expression and activity of this enzyme by GH/IGF1 has been confirmed in
vitro [56], in GH deficient patients treated with GH [57] and in acromegaly patients [58,59].
In addition, we found higher expression of the glucocorticoid receptor (NR3C1, 1.5 fold
q = 0.00013) in acromegaly patients (Fig 2F). Glucocorticoid receptor expression is repressed
by cortisol [60], so the higher expression may be due to the reduced local cortisol levels caused
by lowered HSD11B1.
Summary
In this study we have described a transcriptional signature in adipose tissue from subjects with
acromegaly. We identified 418 adipose tissue genes altered in acromegaly patients. Some of
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these genes may be direct targets of increased GH or IGF-1 signaling in adipose tissue, whereas
others may be secondary adaptations to this condition.
Interestingly, we observed more modest gene expression changes in general for older acro-
megalic patients than for younger patients. We are unable to determine from our study how
long patients were acromegalic prior to our study, so one possibility is that the older patients
have had longer to adapt to elevated GH levels. Alternatively, elevated GH/IGF-1 signaling
may play a stronger role in younger patients. It should be noted, however that this exploratory
finding was limited since we only had 2 acromegalic patients over 60 in our study, so these age-
dependent findings will need to be reproduced in a larger cohort.
The fact that the patients consistently had a relatively uniform change of expression of these
genes suggests that we are able to draw valid conclusions about adipose tissue in acromegalic
patients even from this small cohort. Furthermore, as mentioned throughout, our data agree
with several previous studies in animal models and patients. The confirmation of these previ-
ously reported GH-dependent transcriptional changes strengthens our interpretation of other
transcriptional changes. One potential caveat to our approach is the use of patients with a non-
secreting adenoma as the control group. To avoid the possible effects of hypopituitarism on
adipose tissue we excluded patients with pituitary hormone deficiencies. We chose to include
this as the control group as these samples not only collected in an identical manner from the
same surgeons and processed identically, but also controls for potential non-secreting effects of
pituitary tumor growths in the acromegaly subjects.
A potential caveat is the potential confounding effect of anti-diabetic or anti-growth hor-
mone medications. Only one acromegalic patient was on somatostatin, and his IGF-1 levels
were non-responsive. Our exclusion criteria included any glucocorticoid treatment. One
patient in each group was on metformin as an antidiabetic medication, so we do not feel that
this affected our overall conclusions. Another potential limitation was our inability to reanalyze
the samples by a secondary method for gene expression or to validate our findings at the pro-
tein level, due to a lack of sample. We could not analyze a second cohort due to the rarity of
this disease.
These data provide a variety of novel transcriptional changes that may be causative of the
co-morbidities associated with acromegaly. Further studies in animals and cells using knockout
or overexpression of specific transcripts may verify which of the changes is crucial in metabolic
effects of GH in adipose tissue.
Supporting Information
S1 Fig. Principal component analysis of normalized transcript levels.Normalized counts
were transformed via a regularized log transformation then principal components were calcu-
lated. Samples were then colored based on age and diagnosis. The dotted line indicates the
grouping of samples into groups based on their disease state.
(TIF)
S2 Fig. Expression changes of selected other transcripts.mRNA Expression profile of differ-
entially expressed genes involved in A) MAPK Signaling, B) Cell cycle control, C) Lipolysis and
D) Glycogen metabolism. Asterisks indicate q<0.05. Barplots are presented as mean +/- stan-
dard error of the mean. mRNA Expression is in units of RPKM (reads per kilobase per million
reads).
(TIF)
S3 Fig. Expression changes of selected insulin signal transduction genes.mRNA Expression
profile of genes involved in insulin signaling (A) and inflammation (B). Asterisks indicate
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q<0.05. Barplots are presented as mean +/- standard error of the mean. mRNA Expression is
in units of RPKM (reads per kilobase per million reads).
(TIF)
S4 Fig. Ceramide levels in adipose tissue from control and acronegalic patients. Ceramide
(Cer) or glucosylceramide levels (GluCer) were determined as described in the methods
and materials section. The number indicates the fatty acid species associated with each lipid.
All values are normalized such that control values are equal to 1. Data indicates mean +/- stan-
dard error of the mean.
(TIF)
S1 Table. Expression changes between control and acromegaly subjects. Calculated expres-
sion, and expression changes for each gene are shown along with raw p-value, adjusted p-val-
ues and the fold change.
(CSV)
S2 Table. Age adjusted gene expression changes between control and acromegaly subjects.
Patients were grouped into under-60 and 60 and over as the age and genes were first analyzed
with age group as a covariate then after that adjustment, the disease state was taken into
account. Three log2 fold changes and p-values are presented. The age adjusted effect of Acro-
megaly (AcrovsControl), the effects if acromegaly in only the under 60 group (Acrovs-
Con_0.60) and the effects of acromegaly in only the above 60 group (AcrovsCon_60.100).
(XLS)
S3 Table. Gene set enrichment analysis of GO and KEGG pathways. Size is the total size of
the KEGG category, NES is the normalized enrichment score, NOM p-value is the raw p-value
and FDR q-value is corrected for multiple observations. Gene details lists the specific genes
which led to the enrichment of this category in our data. A negative enrichment score indicates
down-regulation of the category in acromegaly.
(XLS)
S4 Table. Gene set enrichment analysis of transcription factor and miRNA pathways. These
categories indicate that target genes regulated by these factors are altered in acromegalic white
adipose tissue. Size is the total size of the category, NES is the normalized enrichment score,
NOM p-value is the raw p-value and FDR q-value is corrected for multiple observations. Gene
details lists the specific genes which led to the enrichment of this category in our data. A nega-
tive enrichment score indicates down-regulation of the category in acromegaly.
(XLS)
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